BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 12644539)

  • 1. Effects of blocking platelet-derived growth factor-receptor signaling in a mouse model of experimental prostate cancer bone metastases.
    Uehara H; Kim SJ; Karashima T; Shepherd DL; Fan D; Tsan R; Killion JJ; Logothetis C; Mathew P; Fidler IJ
    J Natl Cancer Inst; 2003 Mar; 95(6):458-70. PubMed ID: 12644539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
    Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
    Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting platelet-derived growth factor receptor on endothelial cells of multidrug-resistant prostate cancer.
    Kim SJ; Uehara H; Yazici S; Busby JE; Nakamura T; He J; Maya M; Logothetis C; Mathew P; Wang X; Do KA; Fan D; Fidler IJ
    J Natl Cancer Inst; 2006 Jun; 98(11):783-93. PubMed ID: 16757703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous blockade of platelet-derived growth factor-receptor and epidermal growth factor-receptor signaling and systemic administration of paclitaxel as therapy for human prostate cancer metastasis in bone of nude mice.
    Kim SJ; Uehara H; Yazici S; Langley RR; He J; Tsan R; Fan D; Killion JJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(12):4201-8. PubMed ID: 15205332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
    Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
    Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
    McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
    Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
    Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
    Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma.
    Apte SM; Fan D; Killion JJ; Fidler IJ
    Clin Cancer Res; 2004 Feb; 10(3):897-908. PubMed ID: 14871965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice.
    Kim SJ; Uehara H; Karashima T; Shepherd DL; Killion JJ; Fidler IJ
    Clin Cancer Res; 2003 Mar; 9(3):1200-10. PubMed ID: 12631626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
    Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
    Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased sensitivity to the platelet-derived growth factor (PDGF) receptor inhibitor STI571 in chemoresistant glioma cells is associated with enhanced PDGF-BB-mediated signaling and STI571-induced Akt inactivation.
    Servidei T; Riccardi A; Sanguinetti M; Dominici C; Riccardi R
    J Cell Physiol; 2006 Jul; 208(1):220-8. PubMed ID: 16575905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
    Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
    Sumida T; Kitadai Y; Shinagawa K; Tanaka M; Kodama M; Ohnishi M; Ohara E; Tanaka S; Yasui W; Chayama K
    Int J Cancer; 2011 May; 128(9):2050-62. PubMed ID: 21387285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the platelet-derived growth factor-receptor enhances survival of murine bone endothelial cells.
    Langley RR; Fan D; Tsan RZ; Rebhun R; He J; Kim SJ; Fidler IJ
    Cancer Res; 2004 Jun; 64(11):3727-30. PubMed ID: 15172974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined low-dose imatinib mesylate and paclitaxel lack synergy in an experimental model of extra-osseous hormone-refractory prostate cancer.
    Corcoran NM; Costello AJ
    BJU Int; 2005 Sep; 96(4):640-6. PubMed ID: 16104925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous inhibition of EGFR, VEGFR, and platelet-derived growth factor receptor signaling combined with gemcitabine produces therapy of human pancreatic carcinoma and prolongs survival in an orthotopic nude mouse model.
    Yokoi K; Sasaki T; Bucana CD; Fan D; Baker CH; Kitadai Y; Kuwai T; Abbruzzese JL; Fidler IJ
    Cancer Res; 2005 Nov; 65(22):10371-80. PubMed ID: 16288027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma.
    Kubo T; Piperdi S; Rosenblum J; Antonescu CR; Chen W; Kim HS; Huvos AG; Sowers R; Meyers PA; Healey JH; Gorlick R
    Cancer; 2008 May; 112(10):2119-29. PubMed ID: 18338812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet-derived growth factor receptors: a therapeutic target in solid tumors.
    George D
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):27-33. PubMed ID: 11740804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.